Phase I/II trials of 186Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survival

177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy

(2016) R. P. Baum et al.   JOURNAL OF NUCLEAR MEDICINE

Bone Scan Index predicts outcome in patients with metastatic hormone-sensitive prostate cancer

(2015) Mads H. Poulsen et al.   BJU INTERNATIONAL

Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting 223Ra-dichloride

(2015) Massimiliano Pacilio et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Immunotherapy for prostate cancer: recent developments and future challenges

(2014) Michael T. Schweizer et al.   CANCER AND METASTASIS REVIEWS

Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy

(2014) Christian M. Zechmann et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Phase II Study of Lutetium-177-Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer

(2013) S. T. Tagawa et al.   CLINICAL CANCER RESEARCH

Patient-specific dosimetry for intracavitary 32P-chromic phosphate colloid therapy of cystic brain tumours

(2013) Ana M. Denis-Bacelar et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

(2013) C. Parker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bone Scan Index: A Quantitative Treatment Response Biomarker for Castration-Resistant Metastatic Prostate Cancer

(2012) Elizabeth R. Dennis et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase I study of combined docetaxel and repeated high activity 186Re-HEDP in castration-resistant prostate cancer (CRPC) metastatic to bone (the TAXIUM trial)

(2011) Joyce M. van Dodewaard-de Jong et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Characterising the castration-resistant prostate cancer population: a systematic review

(2011) M. Kirby et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

A Pilot Study on the Feasibility of Real-Time Calculation of Three-Dimensional Dose Distribution for 153Sm-EDTMP Radionuclide Therapy Based on the Voxel S-Values

(2010) Gan Feng et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Radiopharmaceutical and Chemotherapy Combinations in Metastatic Castrate-Resistant Prostate Cancer: A New Beginning?

(2009) Oliver Sartor   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of Concurrent Weekly Docetaxel and Repeated Samarium-153 Lexidronam in Patients With Castration-Resistant Metastatic Prostate Cancer

(2009) Shi-Ming Tu et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Consolidation Docetaxel and Samarium-153 in Patients With Bone Metastases From Castration-Resistant Prostate Cancer

(2009) Karim Fizazi et al.   JOURNAL OF CLINICAL ONCOLOGY